BSI-060T is under clinical development by Pyxis Oncology and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase I drugs for Thyroid Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BSI-060T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BSI-060T overview

BSI-060T is under development for the treatment of solid tumors including colorectal cancer, endometrial cancer, thyroid cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, breast cancer, bladder cancer, cholangiocarcinoma and kidney cancer. It is administered through intravenous route and acts by targeting SIGLEC15. The therapeutic candidate is being developed based on H3 (high-throughput, high-content, high-efficiency) antibody platform and SynAb technology.

The drug candidate was also under development for ovarian cancer, melanoma, squamous cell carcinoma and merkel cell carcinoma.

Pyxis Oncology overview

Pyxis Oncology is an immuno-oncology company that develops antibody drug conjugates (ADC) and immunotherapies for cancer. The company’s pipeline products include PYX-201, PYX-106 and PYX-107. Its PYX-201, is a antibody-drug conjugate, which treats solid tumors; PYX-106, human monoclonal antibody, which treats solid tumors and PYX-107 for melanoma and liposarcoma. The company utilizes its proprietary flexible antibody conjugation technology (FACT) platform to develop ADCs. Pyxis Oncology’s platform technology analyses promising tumor targets and acquire highly specific antibodies to these tumor targets. Pyxis Oncology is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of BSI-060T’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.